Cellcolabs Raises $12M to Scale Mesenchymal Stem Cell Production and Reduce Costs by 90%
核心洞察
Stockholm-based Cellcolabs (搜索) secured $12 million from Titian Life Sciences (搜索) to advance industrial-scale production of GMP-certified mesenchymal stem cells (搜索) for research and clinical applications.
The company operates a GMP-certified facility in Stockholm and supplies MSCs to university hospitals worldwide, supporting projects from preclinical studies to late-stage clinical trials.
Cellcolabs (搜索) aims to reduce MSC costs by 90% by 2035 to increase accessibility for therapeutic applications in cardiovascular prevention (搜索), musculoskeletal repair (搜索), and age-related frailty (搜索).
Stockholm-based biotech Cellcolabs (搜索) has secured $12 million in primary funding from Titian Capital (搜索) via its life sciences platform, Titian Life Sciences (搜索), bringing the company's total funding to $37 million. The investment will support the company's mission to make high-quality mesenchymal stem cells (搜索) (MSCs) accessible and affordable at industrial scale.
Founded in 2021, Cellcolabs (搜索) specializes in manufacturing GMP-certified MSCs using a production protocol refined over more than 20 years at the Karolinska Institutet. The company currently supplies its cells to university hospitals worldwide and to private clients, including professional athletes and public figures.
Industrial-Scale Production Platform
The company operates a GMP-certified facility in Stockholm and maintains an industrial-scale platform for allogeneic MSCs used in both research and clinical contexts. Through collaborations with academic institutions and contract research programs, Cellcolabs (搜索) supports projects spanning from preclinical studies to late-stage clinical trials.
While Cellcolabs (搜索) does not provide direct patient treatments, its subsidiary sponsors international studies in several therapeutic areas, including cardiovascular prevention (搜索), musculoskeletal repair (搜索), and age-related frailty (搜索), utilizing the same Sweden-produced MSCs.
Cost Reduction Goals
The company has set an ambitious target to reduce the cost of MSCs by 90% by 2035, aiming to lower barriers to research and therapeutic applications. According to Dr. Mattias Bernow, CEO of Cellcolabs (搜索), the stem cell field is approaching an inflection point as scientific evidence grows and regulatory pathways clarify, driving unprecedented demand for stem cells.
Strategic Expansion Plans
With this latest investment, Cellcolabs (搜索) plans to advance technical development and expand internationally. The funding will strengthen the infrastructure needed to bring stem cell science into real-world clinical use and support the company's objective to increase accessibility and affordability of high-quality MSCs for research and therapeutic applications.
The company aims to shape the next phase of regenerative medicine and set a new global standard for stem cell access, positioning itself at the forefront of the growing stem cell therapeutics market.